MedTrace Logo

Genoss DES Prospective Multicenter Registry

NCT03045913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-01-30

No results posted yet for this study

Summary

This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring coronary revascularization with Drug Eluting Stents (DES).

Conditions

Interventions

DEVICE

Genoss DES

The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Sponsors & Collaborators

  • Genoss Co., Ltd.

    collaborator INDUSTRY

  • Young Jin Youn, MD, PhD

    lead OTHER

Principal Investigators

  • Junghan Yoon, MD, PhD · Wonju Severance Christian Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-18
Primary Completion
2021-11-29
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03045913 on ClinicalTrials.gov